Radionuklide in der Therapie von Knochenmetastasen
Authors:
- 12 July 2014
- book chapter
- Published by Springer Nature
- p. 95-103
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancerEuropean Journal of Cancer, 2012
- Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-OctreotateJournal of Nuclear Medicine, 2011
- Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and ParagangliomaJournal of Clinical Oncology, 2009
- EANM procedure guideline for treatment of refractory metastatic bone painEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastasesNuclear Medicine Communications, 2007
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Multiple myeloma: Monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapyEuropean Journal of Cancer, 2006
- Radioisotopes for the palliation of metastatic bone cancer: a systematic reviewThe Lancet Oncology, 2005